Loading...
•
Jun 30, 2024
Enliven Therapeutics Q2 2024 Earnings Report
Reported second quarter financial results and provided a business update
Key Takeaways
Enliven Therapeutics reported its second quarter financial results, highlighting the dosing of the first patient in the Phase 1b arm of the ELVN-001 clinical trial and the first patient in the Phase 1a clinical trial of ELVN-002. The company's cash, cash equivalents, and marketable securities totaled $312.4 million, expected to provide cash runway into late 2026.
Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML.
Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ MBC and CRC.
Announced positive proof of concept data from the Phase 1a clinical trial in April.
Cash, cash equivalents and marketable securities totaled $312.4 million, which is expected to provide cash runway into late 2026.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
The company expects to provide additional Phase 1 data in 2025, including data from approximately 60-100 patients across various lines of therapy with significant follow-up. Phase 1 monotherapy data and initial Phase 1a combination data are expected in 2025.